吡仑帕奈单药在胶质瘤唤醒开颅术中癫痫管理的可行性
该回顾性研究纳入24例接受唤醒开颅术的胶质瘤患者,术前给予吡仑帕奈2–4 mg,术中追加静脉2 mg两次。术中癫痫发生3例(12.5%),均为局灶性且经冷盐水冲洗控制,无难治性或全面性发作,无手术失败。术后早期癫痫2例(8.3%),3个月时所有患者发作完全控制,1例(4.2%)因皮疹停药。
要点
- 吡仑帕奈单药在唤醒开颅术中可有效控制围手术期癫痫,术中发作率12.5%且均为局灶性。
- 无难治性发作或全面性发作,无因癫痫导致的手术失败。
- 不良反应率低(4.2%),术后3个月所有患者癫痫完全控制。
核心结论
- 吡仑帕奈单药在该队列中提供了围手术期癫痫控制,不良反应发生率很低,初步支持其可行性并为前瞻性评估提供依据。
研究设计与样本
- 回顾性分析2024年12月至2025年12月在本机构接受唤醒开颅术并接受吡仑帕奈单药治疗的胶质瘤患者。
- 共29例接受唤醒开颅术,排除5例(4例使用多种抗癫痫药物,1例拒绝吡仑帕奈),最终24例纳入分析。
主要发现
- 术中癫痫发生3例(12.5%),均为局灶性,经冷盐水冲洗控制。
- 无难治性或全面性癫痫发作,无唤醒手术失败。
- 术后早期癫痫发生2例(8.3%),术后3个月所有患者癫痫完全控制。
- 治疗相关不良反应1例(4.2%),表现为皮疹并停用吡仑帕奈。
- 22例无术后早期癫痫的患者中,9例在6个月内成功停用抗癫痫药物。
关键数值与推荐
- 术前给予吡仑帕奈2–4 mg。
- 手术当天开始操作时静脉追加吡仑帕奈2 mg,手术结束时再追加2 mg。
临床怎么用
- 对于接受唤醒开颅术的胶质瘤患者,可考虑围手术期使用吡仑帕奈单药预防癫痫。
- 术中局灶性癫痫可通过冷盐水冲洗控制,无需转为全身麻醉。
- 术后无早期癫痫者可在6个月内尝试停用抗癫痫药物。
局限性
- 回顾性设计,样本量小(24例),证据级别有限。
- 单中心研究,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the feasibility of perampanel (PER) monotherapy for perioperative seizure management in patients undergoing awake craniotomy (AC) for glioma, with emphasis on preventing intraoperative intractable seizures. METHODS: A retrospective analysis was conducted on patients who underwent AC at our institution between December 2024 and December 2025 and received PER monotherapy. PER was administered preoperatively at 2–4 mg. On the day of surgery, an additional 2 mg of PER was given intravenously at the start of the procedure and another 2 mg upon completion. RESULTS: Of 29 patients who underwent AC, five were excluded (four on multiple antiseizure medications and one who declined PER treatment), leaving 24 for analysis. Intraoperative seizures occurred in 3 patients (12.5%), all focal and controlled with cold saline irrigation. No intractable or generalized seizures occurred, and no awake procedures failed. Two patients had preoperative epilepsy, whereas one had no prior seizure history. Early postoperative seizures developed in 2 patients (8.3%), and complete seizure control was achieved in all patients by 3 months postoperatively. Treatment-related adverse effects occurred in one patient (4.2%) who developed a skin rash and discontinued PER. Among the 22 patients without early postoperative seizures, antiseizure medications were successfully discontinued within 6 months in 9 patients. CONCLUSION: In this cohort, PER provided perioperative seizure control with a very low incidence of adverse effects. These preliminary findings support the feasibility of PER monotherapy and provide a rationale for prospective evaluation. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Koketsu Y, Deguchi S, Ohka F, et al. Feasibility of perampanel monotherapy for seizure management during awake craniotomy for glioma. J Neurooncol. 2026. PMID: 42029759. doi:10.1007/s11060-026-05580-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。